Septerna Appoints Mark A. Wilson as Chief Legal Officer
SOUTH SAN FRANCISCO, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE) - Septerna, Inc. (Nasdaq: SEPN), a leading clinical-stage biotechnology company in G protein-coupled receptor (GPCR) drug discovery, has announced the appointment of Mark A. Wilson as its new Chief Legal Officer.
Mark A. Wilson's Extensive Experience
Mark A. Wilson brings over 25 years of experience in the pharmaceutical and biotechnology sectors, specializing in intellectual property, corporate legal matters, strategic collaborations, and governance. His experience will be crucial as Septerna continues to evolve its governance structures and enhance the value of its proprietary Native Complex Platform™.
Leadership Quotes
“We are thrilled to welcome Mark to the team,” stated Jeffrey Finer, M.D., Ph.D., CEO and Co-founder of Septerna. “His deep expertise will be instrumental in strengthening our governance framework and maximizing the potential of our portfolio.”
Mark Wilson expressed his enthusiasm, saying, “Septerna represents an extraordinary opportunity to be part of a company that is transforming GPCR drug discovery. I am excited to join this talented team and contribute to the advancement of innovative therapies that have the potential to make a meaningful difference for patients.”
Wilson's Previous Roles and Achievements
Before joining Septerna, Mr. Wilson served as Senior Vice President and Chief Legal Officer at Nektar Therapeutics. There, he led several major global collaborations and strategic transactions while overseeing the company's patent strategy.
- Served on the executive committee at Nektar Therapeutics.
- Joined Nektar in 2002 as Patent Counsel, progressively advancing to General Counsel.
- Originally worked at Reed & Associates, representing start-ups and Fortune 500 companies.
Educational Background
Mark A. Wilson holds a J.D. from Seton Hall University School of Law and a B.S. in Pharmacy from Rutgers University College of Pharmacy. He is also registered to practice before the U.S. Patent and Trademark Office and is a member of the State Bar of California.
About Septerna, Inc.
Septerna, Inc. is at the forefront of GPCR drug discovery, leveraging its Native Complex Platform™ to develop a diverse pipeline of novel oral small molecule drug candidates. The company focuses on therapeutic areas including:
- Endocrinology
- Immunology and Inflammation
- Metabolic Diseases
For more information on Septerna and its innovative pipeline, please visit www.septerna.com.